Clinical Study
Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study
Table 2
Demographic characteristics of patients enrolled in the study.
| | Variables | Treatment | Control | value |
| | Age (SD) | 73.2 (8.7) | 79.2 (8.4) | 0.22 | | Right eyes, (%) | 6 (54.6) | 2 (40.0) | 1 | | CNV type, (%) | 1 | 3 (27.3) | 2 (40.0) | 1 | | 2 | 4 (36.4) | 1 (20.0) | | Mixed | 4 (36.4) | 2 (40.0) | | Duration of AMD prior to randomization (months), median (range) | 18 (12–48) | 12 (6–18) | 0.21 | | Number of previous IVT anti-VEGF, mean (SD) | 8.8 (4.0) | 9.2 (4.1) | 0.86 | | Period of treatment with anti-VEGF before entering into the study (months), median (range) | 13 (6–16) | 11 (8–51) | 0.69 | | OCT-CFT after last anti-VEGF injection before entering into the study (μm), mean (SD) | 387.6 (138.7) | 488.2 (161.9) | 0.22 | | OCT mean macular volume after the last anti-VEGF injection before entering into the study (mm3), median (range) | 7.5 (7.3–7.7) | 10.6 (8.8–11.1) | 0.18 | | BCVA study eye (ETDRS letters), median (range) | 44 (4–70) | 65 (50–69) | 0.33 | | BCVA study eye (logMar), median (range) | 0.82 (0.30–1.62) | 0.40 (0.32–0.70) | 0.33 | | BCVA study eye (Snellen), median (range) | 20/132 (20/40–20/833) | 20/50 (20/42–20/100) | 0.33 | | Pre-op IOP (mmHg), median (range) | 15 (14–17) | 14 (14–16) | 0.6 | | OCT-MT (μm), median (range) | 462 (395–600) | 354 (279–373) | 0.10 | | OCT mean macular volume (mm3), median (range) | 9.7 (8.3–9.8) | 8.3 (8.0–8.4) | 0.23 | | FA leakage area (mm2), median (range) | 2.5 (0.5–5.8) | 3.4 (1.1–6.2) | 0.6 |
|
|
SD: standard deviation; range: minimum and maximum value; CNV: choroidal neovascularization; AMD: age-related macular degeneration; IVT: intravitreal therapy; VEGF: vascular endothelial growth factor; OCT: optical coherence tomography; CFT: central foveal thickness; BCVA: best corrected visual acuity; FA: fluorescein angiography.
|
